about
Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma.Proteomic profiling of patient-derived glioblastoma xenografts identifies a subset with activated EGFR: implications for drug development.Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas.Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis.Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort AnalysisRecurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis.Consultative issues in surgical neuropathology: a retrospective review of the rationale for submitting cases for expert review.Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas.The genomic landscape of TERT promoter wildtype-IDH wildtype glioblastoma.Heterogeneity within the PF-EPN-B ependymoma subgroupComprehensive Analysis of Alternative Splicing Across Tumors from 8,705 PatientsComprehensive Characterization of Cancer Driver Genes and MutationsThe Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell CarcinomaTissue is the Issue: Biomarkers of Prognosis and Classification in Adult GliomasPilot Study to Describe the Trajectory of Symptoms and Adaptive Strategies of Adults Living with Low-grade Glioma
P50
Q33399939-E3BAB21D-8C71-4AD0-8E80-0FAF4638B68EQ35887828-15B0F866-354C-452F-AB08-2C33805B274BQ36236484-E5FFFBFF-6592-424B-87C4-8208BBE8A758Q37004219-2E20C41F-0828-42B2-958A-CAA40374A082Q37130238-7D505AF8-3061-4D12-9D51-652DA7AD5FA8Q37636027-48949998-B034-4500-B419-5F92DB94C005Q38478598-8C25613C-588E-4B5E-AEA8-56BB84A6F87CQ47903338-BB79BFD9-95BE-407E-894F-CDA295CE667FQ55104257-87F0145A-0B2E-4360-BE18-89ABD17DADBBQ57171284-88A08D6B-5F32-4058-B80C-2A9214DC452BQ57261157-0EBD7A0B-707D-4DDC-9558-A72BB0C5C61DQ57261160-1A8704AB-704F-4FF5-ADAE-FEDE88BE4FC6Q57261171-6A1B2646-8A2A-4819-9703-2908CA9BBA0AQ58608879-0B7A0AE0-43DE-4539-8AC8-7014AA433E6DQ58612429-7952BE55-D454-4B13-BB63-727DCF5DD9DF
P50
description
researcher ORCID ID = 0000-0002-4372-5533
@en
name
Eric Lipp
@ast
Eric Lipp
@en
Eric Lipp
@es
Eric Lipp
@nl
type
label
Eric Lipp
@ast
Eric Lipp
@en
Eric Lipp
@es
Eric Lipp
@nl
prefLabel
Eric Lipp
@ast
Eric Lipp
@en
Eric Lipp
@es
Eric Lipp
@nl
P1153
25626345100
P21
P31
P496
0000-0002-4372-5533